文献速递前列腺癌

前列腺癌中前列腺特异性膜抗原异质性与DNA修复缺陷

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
PubMed 文献 · Eur Urol · 2019-07-22

本研究对转移性去势抵抗性前列腺癌(mCRPC)及配对诊断活检组织进行膜性PSMA(mPSMA)免疫组化评分,并与二代测序和临床结局关联。结果显示mPSMA表达在患者间及肿瘤内异质性显著,DNA损伤修复(DDR)缺陷肿瘤mPSMA表达更高。

要点

  • 诊断时mPSMA表达与更高Gleason分级(p=0.04)和更差总生存(p=0.006)相关。
  • mPSMA表达从去势敏感前列腺癌(CSPC)到mCRPC升高,但42% CSPC和27% mCRPC组织无可检测mPSMA。
  • DDR缺陷肿瘤mPSMA表达更高,BRCA2和ATM突变验证队列中mPSMA中位H-score分别为300和212.5。

核心结论

  • 膜性PSMA表达在一些但非全部前列腺癌中上调,呈现显著的患者间和患者内异质性。
  • DDR缺陷与更高的mPSMA表达相关,值得在更大前瞻性队列中进一步评估其作为PSMA靶向治疗反应预测生物标志物的价值。

研究设计与样本

  • 对mCRPC及同一患者配对诊断活检组织进行膜性PSMA(mPSMA)免疫组化评分,并与二代测序(NGS)和临床结局数据关联。
  • mPSMA表达采用改良H-score定量,患者DNA行NGS检测,mCRPC转录组用于基因表达和活性评分。
  • 统计采用Wilcoxon符号秩检验、Kaplan-Meier法估计生存,样本异质性用Shannon多样性指数量化。

主要发现

  • 诊断时mPSMA表达与更高Gleason分级相关(p=0.04),与更差总生存相关(p=0.006)。
  • mPSMA表达从CSPC到mCRPC升高:CSPC中位H-score 17.5(四分位距0.0-60.0) vs mCRPC 55.0(2.8-117.5)。
  • 42%(n=16)的CSPC组织和27%(n=16)的mCRPC组织无可检测mPSMA(H-score <10)。
  • 所有mPSMA表达的CSPC活检(100%)和37例(84%)mCRPC活检中观察到显著瘤内异质性,存在无可检测PSMA的灶区;转移灶间亦存在异质性,肝转移表达最低。
  • DDR缺陷肿瘤mPSMA表达更高(p=0.016;中位H-score 87.5 [25.0-247.5] vs 20 [0.3-98.8];中位数差60 [5.0-95.0])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. OBJECTIVE: To elucidate PC PSMA expression and associate this with defective DNA damage repair (DDR). DESIGN, SETTING, AND PARTICIPANTS: Membranous PSMA (mPSMA) expression was scored immunohistochemically from metastatic castration-resistant PC (mCRPC) and matching, same-patient, diagnostic biopsies, and correlated with next-generation sequencing (NGS) and clinical outcome data. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Expression of mPSMA was quantitated by modified H-score. Patient DNA was tested by NGS. Gene expression and activity scores were determined from mCRPC transcriptomes. Statistical correlations utilised Wilcoxon signed rank tests, survival was estimated by Kaplan-Meier test, and sample heterogeneity was quantified by Shannon's diversity index. RESULTS AND LIMITATIONS: Expression of mPSMA at diagnosis was associated with higher Gleason grade (p=0.04) and worse overall survival (p=0.006). Overall, mPSMA expression levels increased at mCRPC (median H-score [interquartile range]: castration-sensitive prostate cancer [CSPC] 17.5 [0.0-60.0] vs mCRPC 55.0 [2.8-117.5]). Surprisingly, 42% (n=16) of CSPC and 27% (n=16) of mCRPC tissues sampled had no detectable mPSMA (H-score <10). Marked intratumour heterogeneity of mPSMA expression, with foci containing no detectable PSMA, was observed in all mPSMA expressing CSPC (100%) and 37 (84%) mCRPC biopsies. Heterogeneous intrapatient mPSMA expression between metastases was also observed, with the lowest expression in liver metastases. Tumours with DDR had higher mPSMA expression (p=0.016; 87.5 [25.0-247.5] vs 20 [0.3-98.8]; difference in medians 60 [5.0-95.0]); validation cohort studies confirmed higher mPSMA expression in patients with deleterious aberrations in BRCA2 (p<0.001; median H-score: 300 [165-300]; difference in medians 195.0 [100.0-270.0]) and ATM (p=0.005; 212.5 [136.3-300]; difference in medians 140.0 [55.0-200]) than in molecularly unselected mCRPC biopsies (55.0 [2.75-117.5]). Validation studies using mCRPC transcriptomes corroborated these findings, also indicating that SOX2 high tumours have low PSMA expression. CONCLUSIONS: Membranous PSMA expression is upregulated in some but not all PCs, with mPSMA expression demonstrating marked inter- and intrapatient heterogeneity. DDR aberrations are associated with higher mPSMA expression and merit further evaluation as predictive biomarkers of response for PSMA-targeted therapies in larger, prospective cohorts. PATIENT SUMMARY: Through analysis of prostate cancer samples, we report that the presence of prostate-specific membrane antigen (PSMA) is extremely variable both within one patient and between different patients. This may limit the usefulness of PSMA scans and PSMA-targeted therapies. We show for the first time that prostate cancers with defective DNA repair produce more PSMA and so may respond better to PSMA-targeting treatments.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019. PMID: 31345636. doi:10.1016/j.eururo.2019.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。